Travere Therapeutics (TVTX) Interest Expenses (2011 - 2026)
Travere Therapeutics' (TVTX) quarterly Interest Expenses came in at $2.3 million in Q1 2026, down 20.69% YoY from $2.9 million in Q1 2025, and up 4.55% on a QoQ basis from $2.2 million in Q4 2025.
Travere Therapeutics (TVTX) Interest Expenses (2011 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 16 years of Interest Expenses data on file, last reported at $2.3 million in Q1 2026.
- Quarterly Interest Expenses fell 20.69% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.2 million (up 13.72% YoY) and the FY2025 annual result came in at $370.6 million, up 7.68% from the prior year.
- Interest Expenses improved to $2.3 million in Q1 2026, from $2.2 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $21.8 million in Q2 2025 to a low of $438000.0 in Q4 2024.
- A 5-year average of $3.7 million and a median of $2.8 million in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2024 — Interest Expenses tumbled 84.36% — and 2025, when it soared 683.11%.
- Tracing TVTX's Interest Expenses over 5 years: stood at $2.8 million in 2022, then retreated by 0.5% to $2.8 million in 2023, then slumped by 84.36% to $438000.0 in 2024, then surged by 402.28% to $2.2 million in 2025, then increased by 4.55% to $2.3 million in 2026.
- The last three Interest Expenses figures came in at $2.3 million (Q1 2026), $2.2 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 275.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 275.55 Mn |
| Jun 30, 2026 | 275.55 Mn |
| Mar 31, 2026 | 2.30 Mn |
| Mar 31, 2026 | 2.30 Mn |
| Dec 31, 2025 | 2.20 Mn |
| Dec 31, 2025 | 2.20 Mn |
| Sep 30, 2025 | 2.75 Mn |
| Sep 30, 2025 | 2.75 Mn |
| Jun 30, 2025 | 21.83 Mn |
| Jun 30, 2025 | 21.83 Mn |
| Mar 31, 2025 | 2.90 Mn |
| Mar 31, 2025 | 2.90 Mn |
| Dec 31, 2024 | 438,000.00 |
| Dec 31, 2024 | 438,000.00 |
| Sep 30, 2024 | 2.80 Mn |
| Sep 30, 2024 | 2.80 Mn |
| Jun 30, 2024 | 2.79 Mn |
| Jun 30, 2024 | 2.79 Mn |
| Mar 31, 2024 | 2.80 Mn |
| Mar 31, 2024 | 2.80 Mn |